aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
0.8169
+0.0466 (6.05%)
At close: Nov 7, 2025, 4:00 PM EST
0.8026
-0.0143 (-1.75%)
After-hours: Nov 7, 2025, 7:59 PM EST
aTyr Pharma Revenue
aTyr Pharma had revenue of $190.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $190.00K, down -19.15% year-over-year. In the year 2024, aTyr Pharma had annual revenue of $235.00K, down -33.43%.
Revenue (ttm)
$190.00K
Revenue Growth
-19.15%
P/S Ratio
421.29
Revenue / Employee
$2,923
Employees
65
Market Cap
80.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 235.00K | -118.00K | -33.43% |
| Dec 31, 2023 | 353.00K | -10.03M | -96.60% |
| Dec 31, 2022 | 10.39M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 10.46M | 10.03M | 2,377.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ATYR News
- 22 hours ago - aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR - PRNewsWire
- 1 day ago - aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update - GlobeNewsWire
- 2 days ago - aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman - GlobeNewsWire
- 3 days ago - ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ATyr Pharma - GlobeNewsWire
- 8 days ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - GlobeNewsWire
- 8 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Lawsuit - ATYR - PRNewsWire
- 10 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - PRNewsWire
- 15 days ago - ATYR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - PRNewsWire